Contributions
Abstract: EP1628
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease affecting the central nervous system. Interferon (IFN) beta-1a 44ug, dimethyl fumarate (DMF) and fingolimod are well-established medications for the treatment of relapsing-remitting MS (RR MS). The aim of the project (analysis from registry ReMuS) was to compare the efficacy of IFN beta-1a 44 µg, DMF and fingolimod in patients with RR MS. This treatment began within ninety days after relapse in real world evidence in the Czech Republic.
Methods: A total of 279 patients with RR MS, who experienced one relapse after the treatment with IFN beta-1a 22 µg given 3 times weekly, IFN beta-1a 30 µg given once weekly, IFN beta-1b 250 ug given every other day, teriflunomid 14 mg given daily, glatiramer acetate 20 mg given daily, or glatiramer acetate given 40 mg given 3 times weekly, as well as those who switched the treatment to IFN beta-1a 44ug, DMF or fingolimod, were included into the study. The observed parameters were annualized relapse rate (ARR), time to the first relapse, proportion of relapse free patients and change in EDSS at 1‐year of treatment.
Results: We found out a significant improvement in the observed outcomes during one-year observation. A comparison of IFN beta-1a 44ug group (83 patients) vs. DMF and fingolimod group (196 patients) showed a more significant improvement in the observed parameters (ARR and change of EDSS) in DMF and fingolimod group. When we used method propensity score matching (83 patients IFN beta-1a 44ug group vs. 83 patients DMF and fingolimod group), the sustained improvement in the observed parameters persisted before and after the change of the treatment in both groups but no significant differences were observed between the groups.
Conclusion: IFN beta-1a 44ug, DMF and fingolimod are effective in the escalation of the treatment (parameters - change of EDSS and time to the next relapse).
Disclosure: The authors declare that there is no conflict of interest.
Abstract: EP1628
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease affecting the central nervous system. Interferon (IFN) beta-1a 44ug, dimethyl fumarate (DMF) and fingolimod are well-established medications for the treatment of relapsing-remitting MS (RR MS). The aim of the project (analysis from registry ReMuS) was to compare the efficacy of IFN beta-1a 44 µg, DMF and fingolimod in patients with RR MS. This treatment began within ninety days after relapse in real world evidence in the Czech Republic.
Methods: A total of 279 patients with RR MS, who experienced one relapse after the treatment with IFN beta-1a 22 µg given 3 times weekly, IFN beta-1a 30 µg given once weekly, IFN beta-1b 250 ug given every other day, teriflunomid 14 mg given daily, glatiramer acetate 20 mg given daily, or glatiramer acetate given 40 mg given 3 times weekly, as well as those who switched the treatment to IFN beta-1a 44ug, DMF or fingolimod, were included into the study. The observed parameters were annualized relapse rate (ARR), time to the first relapse, proportion of relapse free patients and change in EDSS at 1‐year of treatment.
Results: We found out a significant improvement in the observed outcomes during one-year observation. A comparison of IFN beta-1a 44ug group (83 patients) vs. DMF and fingolimod group (196 patients) showed a more significant improvement in the observed parameters (ARR and change of EDSS) in DMF and fingolimod group. When we used method propensity score matching (83 patients IFN beta-1a 44ug group vs. 83 patients DMF and fingolimod group), the sustained improvement in the observed parameters persisted before and after the change of the treatment in both groups but no significant differences were observed between the groups.
Conclusion: IFN beta-1a 44ug, DMF and fingolimod are effective in the escalation of the treatment (parameters - change of EDSS and time to the next relapse).
Disclosure: The authors declare that there is no conflict of interest.